kanamycin a has been researched along with clofazimine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cai, G; Cho, S; Franzblau, SG; Jaki, BU; Lee, IA; McAlpine, JB; Napolitano, JG; Pauli, GF; Suh, JW; Wang, Y; Yang, SH | 1 |
| Centárová, I; Cole, ST; Čonka, P; Hrabálek, A; Karabanovich, G; Klimešová, V; Mikušová, K; Němeček, J; Pávek, P; Pávková, I; Roh, J; Šarkan, M; Smutný, T; Stolaříková, J; Székely, R; Vávrová, K; Vejsová, M; Vocat, A; Zemanová, J | 1 |
| Bera, S; Mondal, D | 1 |
| Saito, H; Sato, K; Tomioka, H | 1 |
| Saito, H; Sato, K | 1 |
| Hassan, G; Kant, S; Parengal, J; Saheer, S | 1 |
| Chiang, CY; Madan, J; Meredith, SK; Nunn, AJ; Phillips, PP; Rusen, ID; Squire, SB; Torrea, G; Van Deun, A | 1 |
| Aung, KJ; Das, PK; Declercq, E; Hossain, MA; Rieder, HL; Sarker, MR; Van Deun, A | 1 |
| Boukary, I; Daouda, M; Hanki, Y; Harouna, SH; Morou, S; Piubello, A; Souleymane, MB; Van Deun, A | 1 |
| Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A | 1 |
| Aggarwal, R; Nemade, P; Panjwani, T; Purohit, S | 1 |
| Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
| Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM | 1 |
| Affolabi, D; de Jong, BC; Decroo, T; Dusabe, T; Habimana, YM; Migambi, P; Mulders, W; Ngabonziza, JCS; Niyigena, EB; Rigouts, L; Supply, P; Ushizimpumu, B; Van Deun, A | 1 |
| Dhamija, RK; Garg, D; Saroha, D; Singh, AK | 1 |
| Barilar, I; Cirillo, DM; Farhat, MR; Freschi, L; Köser, CU; Miotto, P; Niemann, S; Spitaleri, A; Tahseen, S; Vargas, R | 1 |
2 review(s) available for kanamycin a and clofazimine
| Article | Year |
|---|---|
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
1 trial(s) available for kanamycin a and clofazimine
| Article | Year |
|---|---|
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Moxifloxacin; Prothionamide; Pyrazinamide; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
16 other study(ies) available for kanamycin a and clofazimine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular; Peptides, Cyclic; Streptomyces; Vero Cells | 2013 |
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacteria; Cell Line; Cell Survival; Drug Design; Drug Resistance, Multiple, Bacterial; Fungi; Humans; Latent Tuberculosis; Microbial Sensitivity Tests; Microsomes; Mutagens; Mycobacterium tuberculosis; Oxazoles; Primary Cell Culture; Rifampin; Structure-Activity Relationship; Thiadiazoles | 2016 |
[Therapeutic efficacy of kanamycin and clofazimine combined with muramyl dipeptide against Mycobacterium intracellulare infection induced in mice].
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Clofazimine; Drug Evaluation; Drug Therapy, Combination; Female; Kanamycin; Mice; Mice, Inbred Strains; Mycobacterium avium; Tuberculosis | 1991 |
Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice.
Topics: Animals; Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Ethambutol; Female; Kanamycin; Liver; Lung; Mice; Mice, Inbred C57BL; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Rifabutin; Rifamycins; Spleen | 1989 |
Extra-pulmonary primary multidrug-resistant tubercular lymphadenitis in an HIV negative patient.
Topics: Adult; Antitubercular Agents; Clarithromycin; Clofazimine; Cycloserine; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Ethionamide; Female; HIV Seronegativity; Humans; Isoniazid; Kanamycin; Ofloxacin; Pyrazinamide; Rifampin; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant | 2012 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Humans; Kanamycin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mycobacterium tuberculosis; Prospective Studies; Pyrazinamide; Risk Factors; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Clofazimine; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ethambutol; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; HIV Infections; Humans; Kanamycin; Male; Middle Aged; Niger; Prospective Studies; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence Intervals; Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Kanamycin; Male; Medication Adherence; Middle Aged; Odds Ratio; Prospective Studies; Prothionamide; Pyrazinamide; Risk Assessment; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2015 |
XDR TB presenting as a transphyseal lytic lesion in the proximal tibia.
Topics: Antitubercular Agents; Child, Preschool; Clofazimine; Cycloserine; Extensively Drug-Resistant Tuberculosis; Humans; Kanamycin; Tibia; Tuberculosis, Osteoarticular | 2015 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |
Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; High-Throughput Nucleotide Sequencing; Humans; Kanamycin; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Rwanda; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2020 |
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diarylquinolines; Ethionamide; Extensively Drug-Resistant Tuberculosis; Female; Humans; Kanamycin; Linezolid; Neural Conduction; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazinamide; Pyridoxine; Tuberculosis, Pulmonary | 2020 |
Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex.
Topics: Amikacin; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Epistasis, Genetic; Humans; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |